{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:44:58Z","timestamp":1788371098767,"version":"build-2803163510"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to assess the yield of somatostatin receptor PET in patients with clinical, imaging, and\/or biochemical suspicion of a neuroendocrine tumor (NET).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>This analysis includes patients referred for the initial diagnosis of an unconfirmed NET, as part of a prospective, single-arm registry study (NCT03873870) assessing the utility of <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT in the management of NETs. Inclusion criteria to this cohort consisted of elevated biomarkers and\/or clinical presentation suspicious for a NET, with negative conventional cross-sectional imaging, or presence of a lesion suspicious for a NET on conventional imaging, not amenable for biopsy. Patients with histological confirmation of a NET were excluded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There were 220 patients included between April 2019 and March 2022 with a mean age \u00b1 SD of 59.5 \u00b1 16.1 years with biochemical, morphological, and\/or clinical suspicion of a NET. Overall, 132\/220 patients (60%) had a positive <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT. <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT confirmed a type 2 somatostatin receptor overexpressing tumor in 123\/171 (71.9%) of patients with a radiographically suspicious abnormality. The positivity rate for pancreatic, small bowel\/mesenteric, adrenal, and other sites was 78\/96 (81.2%), 38\/57 (66.7%), 7\/7 (100%), and 1\/11 (9.1%), respectively. <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT was positive in 9\/49 (18.4%) of those with a biochemical and\/or clinical suspicion of a NET.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT is positive in nearly 3 of 4 patients with morphological suspicion of a NET, with the highest yield in those with pancreatic and small bowel or mesenteric masses, and in approximately 1 of 6 patients with biochemical and\/or clinical suspicion of a NET.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004829","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T20:03:28Z","timestamp":1694635408000},"page":"933-936","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["68Ga-DOTATATE PET\/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and\/or Biochemical Suspicion of a Neuroendocrine Tumor"],"prefix":"10.1097","volume":"48","author":[{"given":"Ur","family":"Metser","sequence":"first","affiliation":[{"name":"Medical Imaging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[{"name":"Medicine, University Health Network, Mount Sinai Hospital and Women\u2019s College Hospital, University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Rahimi","sequence":"additional","affiliation":[{"name":"Medical Imaging"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Surgery, London Health Sciences Centre\u2013Victoria Hospital, Western University, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singnurkar","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.2967\/jnumed.120.257808","article-title":"Updates to the appropriate-use criteria for somatostatin receptor PET","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","article-title":"68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12149-015-0973-7","article-title":"Additional information gained by positron emission tomography with 68Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors","volume":"29","year":"2015","journal-title":"Ann Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2478\/raon-2014-0018","article-title":"Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: evaluation of Ga-68 DOTATOC PET\/CT and In-111 DTPA octreotide SPECT\/CT","volume":"48","year":"2014","journal-title":"Radiol Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/RLU.0000000000000863","article-title":"Intrapancreatic accessory spleen mimicking neuroendocrine tumor on 68Ga-DOTATATE PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/RLU.0000000000004626","article-title":"False-positive uptake in splenic hemangioma on 68 Ga-DOTATATE PET\/CT","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/thy.2016.0174","article-title":"The rate and clinical significance of incidental thyroid uptake as detected by gallium-68 DOTATATE positron emission tomography\/computed tomography","volume":"26","year":"2016","journal-title":"Thyroid"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"57","year":"2016","journal-title":"J Nucl Med"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/RLU.0000000000004062","article-title":"New biomarkers with prognostic impact based on multitracer PET\/CT imaging in neuroendocrine neoplasms: the light leading out of the darkness in challenging tumors","volume":"47","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004829","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:05:29Z","timestamp":1750532729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004829","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}